Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
237.4 CHF | -2.51% | -0.47% | -8.62% |
05-27 | Roche renews diagnostic partnership with Hitachi | CF |
05-27 | Roche appoints Director of Corporate Business Development | CF |
Sales 2024 * | 60.14B 65.88B 5,169B | Sales 2025 * | 63.69B 69.78B 5,474B | Capitalization | 185B 203B 15,891B |
---|---|---|---|---|---|
Net income 2024 * | 13.43B 14.72B 1,155B | Net income 2025 * | 14.9B 16.32B 1,280B | EV / Sales 2024 * | 3.3 x |
Net Debt 2024 * | 13.78B 15.09B 1,184B | Net Debt 2025 * | 7.83B 8.57B 673B | EV / Sales 2025 * | 3.03 x |
P/E ratio 2024 * |
13.3
x | P/E ratio 2025 * |
12.1
x | Employees | - |
Yield 2024 * |
4.28% | Yield 2025 * |
4.41% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | -2.51% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 31/12/02 | |
Severin Schwan
CHM | Chairman | 57 | 31/12/07 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 31/03/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 02/03/15 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 31/12/95 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.47% | 238B | |
+7.35% | 204B | |
+4.23% | 161B | |
-1.70% | 160B | |
-1.31% | 120B |
- Stock Market
- Equities
- ROG Stock
- RO Stock